to accommodate essential protein translation 1,2 . However, despite increased levels of phosphorylated eIF2α (p-eIF2α), a TLR-TRIF-dependent pathway assures that the cells avoid CHOP induction, apoptosis and translational suppression of critical proteins 3 . As p-eIF2α decreases the functional interaction of eIF2 with eIF2B, a guanine nucleotide exchange factor (GEF), we explored the hypothesis that TLR-TRIF signalling activates eIF2B GEF activity to counteract the effects of p-eIF2α. We now show that TLR-TRIF signalling activates eIF2B GEF through PP2A-mediated serine dephosphorylation of the eIF2B ε-subunit. PP2A itself is activated by decreased Src-family-kinase-induced tyrosine phosphorylation of its catalytic subunit. Each of these processes is required for TLR-TRIF-mediated CHOP suppression in ER-stressed cells in vitro and in vivo. Thus, in the setting of prolonged, physiologic ER stress, a unique TLR-TRIF-dependent translational control pathway enables cells to carry out essential protein synthesis and avoid CHOP-induced apoptosis while still benefiting from the protective arms of the UPR.
physiologic uninterrupted UPR response, prolonged expression of CHOP and suppression of global protein synthesis would have to be at least partially abrogated. In the case of macrophages exposed to activators of TLR4 or TLR3, this function is effected by a pathway downstream of the adaptor TRIF (also known as TICAM1) that suppresses ATF4 translation and subsequent CHOP induction and maintains global translation in the presence of normal PERK activation and eIF2α phosphorylation 3 . When this pathway is blocked in mice, ER-stressinduced CHOP induction, cell death and organ dysfunction ensue 3 .
The goal of this study was to elucidate the molecular signalling components of this adaptive pathway. The above findings indicated that the pathway somehow renders the cells 'resistant' to p-eIF2α, which functions by tightly binding an essential ternary complex GTPexchange factor (GEF) called eIF2B in a manner that competitively inhibits GDP-GTP exchange on the γ-subunit of eIF2 (ref. 7) . In this context, we explored the hypothesis that TLR-TRIF increases the level of eIF2B GEF activity, which might enable adequate GDP-GTP exchange, in the presence of p-eIF2α.
We first determined whether TLR-TRIF signalling increases the level of eIF2B GEF activity in ER-stressed cells. Macrophages from wild-type and Trif −/− mice were treated with the ER stressor tunicamycin alone or after pre-treatment of the cells with the TLR4 activator lipopolysaccharide (LPS). As expected from the increase in the level of p-eIF2α in ER-stressed cells 4 , tunicamycin suppressed eIF2B GEF activity in both wild-type and Trif −/− macrophages (Fig. 1a ). However, in LPS-treated wild-type but not Trif −/− ER-stressed macrophages, the level of eIF2B GEF activity was increased to that of the control. Thus, TLR-TRIF signalling restores ER-stress-suppressed eIF2B GEF activity to the non-ER-stress level.
One mechanism of eIF2B GEF activation is through dephosphorylation of a pSer residue (termed Ser GSK after the kinase that can phosphorylate it 8 ) in the ε-subunit of eIF2B (refs 8,9) . LPS pre-treatment partially decreased the pSer GSK -eIF2Bε in both tunicamycin-treated cells and in untreated wild-type but not Trif −/− cells (Fig. 1b,c) . Thus, (a) Macrophages from wild-type or Trif −/− mice were untreated (Con) or pre-treated (or not) with LPS (1 ng ml −1 ) for 24 h followed by a 3 h treatment with tunicamycin (TN, 1 µg ml −1 ). eIF2B GEF activity was then assayed. Data are expressed as mean ± s.e.m. with n = 6; bars with different symbols are statistically different from each other, P ≤ 0.02. (b) Cells were treated similarly to those in a, except an LPS-alone group was included, and then extracts were analysed by immunoblot analysis (top) for p-eIF2Bε and total eIF2Bε and β-actin as a loading control. Densitometric quantification of the immunoblot data is shown in the histogram as mean ± s.e.m. with n = 3. # ,P < 0.05. (c) The same as in b, except macrophages from wild-type and Trif −/− mice were compared, and data for 7 h of tunicamycin treatment are also shown. # ,P < 0.05; NS, not significant. Uncropped images of blots are shown in Supplementary Fig. S6 .
TRIF is required for the ability of LPS to both increase the level of eIF2B GEF activity and to decrease the level of eIF2B phosphorylation. The hypothesis predicts that the need for LPS to suppress CHOP could be bypassed by increasing the level of eIF2B GEF activity by an LPS-independent means. We investigated this idea by transfecting murine embryonic fibroblasts (MEFs) with wild-type or S-A GSK -mutant rat Eif2be (ref. 10) , which should be particularly potent because it cannot be deactivated by phosphorylation (S. Kimball, unpublished data). We first showed that LPS suppresses p-eIF2Bε, CHOP and CHOP-promoter-driven green fluorescent protein (GFP) reporter expression in ER-stressed MEFs ( Supplementary Fig. S1a,b ), and CHOP suppression was not affected by the transfection reagent, Lipofectamine ( Fig. 2a , groups 1-5). Transfection with S-A GSK Eif2be, which resulted in a level of total Eif2be mRNA (wild-type + mutant) that was approximately twice the endogenous level ( Fig. 2a, right) , mimicked the effect of LPS in terms of suppressing CHOP expression ( Fig. 2a , group 6). Transfection with wild-type Eif2be also resulted in CHOP suppression ( Fig. 2a, group 7) , but the level of suppression was less than that seen with S-A GSK Eif2be. Thus, increasing eIF2Bε in ER-stressed MEFs, especially when the ε subunit cannot be phosphorylated, mimics the effect of LPS on CHOP suppression.
We then conducted a series of experiments in which we first silenced endogenous eIF2Bε using a short interfering RNA (siRNA) that targets mouse but not human (h) EIF2BE, followed by transfection of these cells with one of various hEIF2BE constructs. The siRNA effectively silenced endogenous eIF2Bε, and the decrease in the level of eIF2Bε was associated with a decrease in LPS-induced CHOP suppression ( Fig. 2b, upper left) . This finding is consistent with the model, because there would be very little GEF to be activated by the eIF2Bε dephosphorylation pathway.
We next transfected the silenced cells with a construct encoding human eIF2Bε with serine-alanine point mutations in both the GSK site and an upstream serine residue, which, when phosphorylated by the kinase DYRK, promotes phosphorylation of the GSK site 8, 9 (S-A GSK/DYRK ). This mutant, which cannot be phosphorylated, should be in a constitutively active state that should promote 'resistance' to p-eIF2α and thereby blunt ER-stress-induced CHOP induction (see Fig. 2a ). Most importantly, if LPS suppresses CHOP by decreasing the level of eIF2Bε phosphorylation, it should have little effect in these cells, because, in the absence of phosphorylation, the mutant cannot be dephosphorylated. The data bear out this prediction: compared with MEFs transfected with wild-type hEIF2BE, those transfected with S-A GSK/DYRK hEIF2BE showed a lower level of CHOP expression in response to tunicamycin and no significant further decrease in the CHOP level with LPS pre-treatment ( Fig. 2b , upper right). Finally, using serine-aspartic acid mutants to mimic constitutive phosphorylation, we showed that transfection with S-D GSK/DYRK EIF2BE did not restore LPS-induced CHOP suppression in Eif2be-silenced MEFs (Fig. 2b , lower left). Note that the level of total eIF2Bε in cells with silenced endogenous protein plus transfected human protein was similar to the level of endogenous eIF2Bε in non-silenced, non-transfected cells ( Fig. 2b , lower right). These combined data provide further evidence that eIF2Bε dephosphorylation plays an important role in LPS-mediated suppression of CHOP in ER-stressed cells.
In theory, LPS could lead to a decreased level of p-eIF2Bε by decreasing GSK3 activity. However, we found that LPS did not increase the level of the inactive phosphorylated form of GSK3β ( Supplementary Fig. S2a ) or GSK3α. Moreover, treatment with the phosphatidylinositol-3-OH kinase inhibitor LY294002, which activates GSK3β (ref. 11), did not prevent the LPS-mediated suppression of CHOP (data not shown). These data indicated that a phosphatase might be involved, which we investigated by incubating cell extracts with [ 32 P]eIF2Bε and monitoring the rate of 32 P dephosphorylation. LPS treatment enhanced the level of dephosphorylation in wild-type but not Trif −/− macrophages ( Fig. 3a ). Moreover, the enhanced level of dephosphorylation was suppressed by the phosphatase inhibitor okadaic acid ( Fig. 3a) but not by inhibitors of MAPK phosphatase 1, PP1 and PP2B (data not shown). As okadaic acid can inhibit PP2A, we tested the effect of siRNA-mediated silencing of the catalytic 'C' subunit of PP2A. Compared with scrambled RNA, Pp2ac siRNA prevented the LPS-mediated decrease in both p-eIF2Bε and CHOP levels in ER-stressed macrophages (Fig. 3b ). Note that Pp2ac siRNA also prevented the LPS-mediated decrease in the level of ATF4 ( Supplementary Fig. S2b ), which we showed previously is the most proximal translational target of the 'p-eIF2α resistance' pathway 3 . Finally, we found that a constitutively active mutant of PP2A with a Y307F mutation in the catalytic subunit 12 was able to mimic the effect of LPS on suppression of CHOP ( Fig. 3c, left) . Conversely, a dominant-negative mutant with an L199P mutation in the catalytic subunit 13 prevented LPS-mediated CHOP suppression ( Fig. 3c, right) . These combined results provide evidence for a pathway in which LPS pre-treatment of ER-stressed cells activates PP2A-mediated dephosphorylation of eIF2Bε, resulting in suppression of CHOP.
PP2A can be activated by an increase in the expression of one or more of its three subunits; a decrease in the association of PP2Ac with the inhibitors ANP32 or α-4 (refs 14,15); or dephosphorylation of the catalytic subunit at Tyr 307 (ref. 16 ). LPS pre-treatment did not affect the expression of any of the PP2A subunits or association of PP2Ac with ANP32 or α-4 (data not shown). However, LPS pre-treatment led to a subtle but reproducible and statistically significant decrease in pTyr307-PP2Ac in wild-type but not Trif −/− macrophages ( Fig. 3d ). To investigate this point in vivo, we took advantage of the fact that LPS pre-treatment of tunicamycin-treated mice suppresses CHOP expression, but not eIF2α phosphorylation, in the liver and kidney in a TRIF-dependent manner 3 . We found that LPS pre-treatment led to a decrease in the levels of p-eIF2Bε and p-PP2Ac in liver and kidney extracts of tunicamycin-treated mice (Fig. 3e,f ), similar to our observations in cultured macrophages and MEFs.
Src-family kinases (SFKs) can phosphorylate PP2Ac at Tyr 307 and thereby inhibit PP2A phosphatase activity [16] [17] [18] , and so a decrease in SFK activity could be a mechanism of PP2A activation. Consistent with this possibility, we found that LPS partially decreased the level of phospho-Tyr-p60 c-src (p-Src), a measure of Src activation 19 , in wild-type but not Trif −/− macrophages ( Fig. 4a ) and inhibited the kinase activity of immunoprecipitated Src (Fig. 4b ). Poly(I:C), a ligand for the TLR3-TRIF pathway that is a potent suppressor of CHOP in ER-stressed macrophages 3 , also promoted the dephosphorylation of both Src and PP2Ac ( Supplementary Fig. S2c ). To determine causation, we investigated the effect of a phosphopeptide (EPQ[pY]EEIPIYL) that activates SFKs by binding to and inhibiting their auto-inhibitory SH2 domains 20, 21 and found that it abrogated LPS-induced suppression of both p-PP2Ac and CHOP without increasing the level of p-eIF2α ( Fig. 4c ). The changes in CHOP protein seen with LPS and Src activator treatment were paralleled by changes in Chop mRNA (Fig. 4c , bottom right), which is consistent with the fact that the overall pathway involves ATF4-induced Chop mRNA (ref. 3) . Moreover, the 'p-eIF2α resistance' hypothesis predicts that activation of SFKs would prevent LPS-induced enhancement of global translation in ER-stressed cells 3 . Indeed, by quantifying newly synthesized [ 35 S]-labelled proteins, we found that the SFK peptide activator abrogated the LPS-induced increment in the level of new protein translation in tunicamycin-treated macrophages ( Fig. 4d ).
To determine whether SFK inhibition could mimic the effect of LPS, ER-stressed cells were treated with the SFK inhibitors PP1 or Su6656, and each was found to suppress p-PP2Ac and CHOP in the absence of LPS ( Fig. 4e ). Similar data were obtained using immunofluorescence microscopy assays: LPS treatment led to a decrease in the level of the p-Src signal in wild-type but not Trif −/− macrophages either in the absence or presence of tunicamycin ( Supplementary Fig. S2d,e ), and both LPS and PP1 decreased the level of the p-PP2Ac signal in tunicamycin-treated cells ( Supplementary  Fig. S2f ). As further evidence for the role of SFKs in the pathway, we found that CHOP suppression by the SFK inhibitors was lessened substantially by Pp2ac silencing ( Supplementary Fig. S3a ), indicating that this action of the SFK inhibitors requires PP2Ac. Moreover, MEFs transfected with a dominant-negative form of Src (K296R-Y528F) that acts as a pan-SFK inhibitor 22 mimicked the ability of LPS to suppress tunicamycin-induced CHOP expression ( Supplementary  Fig. S3b ). This construct also suppressed hepatic p-PP2Ac, p-eIF2Bε and CHOP when introduced into the tunicamycin mouse model described above ( Supplementary Fig. S3c ). These combined data provide strong support for the role of SFK inhibition in the TLR-PP2A-eIF2Bε-CHOP pathway. LPS promotes dephosphorylation of eIF2Bε through a mechanism involving PP2A, with evidence in vivo. (a) Macrophages from wild-type or Trif −/− mice were untreated (Con) or pre-treated (or not) with LPS (1 ng ml −1 ) for 24 h followed by treatment with tunicamycin (TN, 1 µg ml −1 ) for 90 min. In an additional LPS/TN group, the phosphatase inhibitor okadaic acid (1 nM) was added at the same time as LPS. Cell extracts were then added to a solution of purified 32 P-labelled eIF2Bε, and the rate of dephosphorylation was determined as described in the Methods. Data are expressed as mean ± s.e.m. with n = 6; * P < 0.05, compared with the control (Con) and the corresponding Trif −/− group. * * P < 0.05, compared with the TN group and the corresponding Trif −/− group. (b) Macrophages were transfected with scrambled RNA or Pp2ac siRNA, and 48 h later the cells were treated similarly to the first three wild-type groups in a. Cell extracts were analysed by immunoblot (left) for p-eIF2Bε and total eIF2Bε, CHOP, PP2Ac and β-actin. The data were then quantified by densitometry (right). * P < 0.05 and * * P < 0.02 versus the TN group in the scrambled RNA groups. (c) MEFs were either mock-transfected or transfected with a plasmid encoding PP2Ac with a Tyr307-phenylalanine mutation or a Leu199-proline mutation. At 12 h post-transfection, cells were then treated ±LPS (500 ng ml −1 ) for 8 h followed by a 2 h treatment with tunicamycin (0.5 µg ml −1 ). Cell extracts were subjected to immunoblot analysis for CHOP and β-actin (top). Densitometric quantification of the immunoblot data is shown in the histograms (bottom). * P < 0.001 versus the TN group; # P < 0.03 versus the LPS/TN group; NS, not significant. (d) Macrophages from wild-type or Trif −/− mice were untreated (Con) or pre-treated (or not) with LPS (1 ng ml − 1) for 24 h followed by treatment with tunicamycin (1 µg ml −1 ) for 3 h. Extracts were analysed by immunoblot for p-PP2Ac and total PP2Ac (left) and then quantified by densitometry (right); * P < 0.05 versus the control and TN groups for wild-type macrophages and versus all groups for Trif −/− macrophages. (e) Mice were injected intravenously with LPS (80 µg kg −1 ) or vehicle control once a day for 2 consecutive days and then injected with tunicamycin (1 mg kg −1 ) intraperitoneally. Twelve hours later, the mice were killed, and liver extracts were assayed by immunoblot for p-PP2Ac and total PP2Ac, p-eIF2Bε and total eIF2Bε, and β-actin (left) and then quantified by densitometry (right). * P = 0.04; * * P = 0.0004; # P = 0.015. (f) The same as in e, except the mice were killed 24 h after the tunicamycin injection, and kidney extracts were assayed. * P = 0.02, compared with the control; * * P = 0.04, compared with the TN group. + P < 0.05, compared with the TN group; # P < 0.01, compared with the TN group. All densitometry data are expressed as mean ± s.e.m. with n = 3, except n = 4 for e and f. Uncropped images of blots are shown in Supplementary Fig. S6 . (e) Macrophages were untreated or pre-treated (or not) with LPS (1 ng ml −1 ) for 24 h followed by treatment with tunicamycin (1 µg ml −1 ) for 3 h (for PP2Ac) or 7 h (for CHOP). Some of the tunicamycin-treated cells were co-treated with the SFK inhibitors PP1 (10 µM) or Su6656 (Su; 20 µM). Extracts were analysed by immunoblot for p-PP2Ac and total PP2Ac, CHOP and β-actin (left) and then quantified by densitometry (right). n = 3; * P < 0.05. All data are expressed as mean ± s.e.m. with n as indicated above. Uncropped images of blots are shown in Supplementary Fig. S6 . Uncropped images of blots are shown in Supplementary Fig. S7 .
We speculate that this TRIF-CHOP suppression pathway protects cells from CHOP-induced apoptosis during LPS-induced sepsis. Indeed, when the pathway is disabled by TRIF deficiency in high-dose (hd) LPS-treated mice, where hd-LPS is both the inducer of ER stress and the activator of the TLR-TRIF-CHOP suppression pathway, we observed an elevated level of CHOP, cell death and organ dysfunction in spleen, liver and kidney 3 . In hd-LPS-treated macrophages, where CHOP expression and apoptosis were suppressed in wild-type but not Trif −/− macrophages (Fig. 5a ), the level of phosphorylation of PP2Ac, eIF2Bε and Src was subtly but reproducibly reduced in a TRIF-dependent manner ( Fig. 5b and Supplementary Fig. S4a-c) . Moreover, hd-LPS treatment of wild-type, but not Trif −/− , mice caused a marked decrease in the level of both p-PP2Ac and p-eIF2Bε in liver ( Fig. 5c ) and kidney (data not shown). As tests of causation, we found that Pp2ac siRNA and Src activator peptide increased the level of CHOP expression in hd-LPS-treated macrophages, and the Src activator also increased the level of CHOP-dependent apoptosis (Fig. 5d,e ).
We reason that the pathway also maintains uninterrupted synthesis of key proteins needed for a proper LPS-induced inflammatory response by promoting 'resistance' to the translational inhibitory effect of p-eIF2α (see Fig. 4d ). We first showed that TRIF deficiency blocked the hd-LPS-induced increase in secreted, immunoreactive stimulated TNFα ( Supplementary Fig. S4d ). To distinguish between transcriptional and translational regulation, we conducted a [ 35 S]methionine-cysteine labelling experiment and found that hd-LPS increased the level of labelled [ 35 S]TNFαin the medium of wild-type but not Trif −/− macrophages ( Supplementary Fig. S4e ). This result cannot be explained by a decreased level of processing or secretion of TNFα in Trif −/− macrophages, because approximately equal amounts of immunoprecipitated TNFα protein were loaded in each lane of the gel. Most importantly, when we directly examined newly translated TNFα by conducting a short-term labelling experiment at a time when Tnfa mRNA levels were similar among all groups (Fig. 5f inset), we found a marked decrease in the level of newly translated pro-TNFα. Together, these data support the idea that the TRIF pathway described herein enables uninterrupted translation of Tnfa mRNA.
The data in this report provide evidence for an eIF2B dephosphorylation-GEF activation pathway that initially involves SFK de-activation and then PP2A activation ( Supplementary Fig. S5 ). We reason that activation of eIF2B by this pathway boosts the level of GTP exchange on eIF2 enough to enable proper ternary complex cycling despite the presence of p-eIF2α (refs 8,23) . One possibility is that ε-dephosphorylated eIF2B can exchange GDP for GTP with higher-than-normal efficiency on the subpopulation of eIF2 complexes whose α-subunit escapes PERK-mediated phosphorylation, thus compensating for the translation-inhibitory and CHOP-inducing effects of the eIF2 complexes whose α-subunit is phosphorylated. Another possibility is that dephosphorylated eIF2B could carry out its GEF function on eIF2 complexes that do have α-subunit phosphorylation, for example, through a conformation change in dephosphorylated eIF2B that might increase its off-rate from the inhibitory site on p-eIF2α and thus enable GDP-GTP exchange on the γ-subunit of eIF2. Regardless of mechanism, restoration of protein translation initiation would both suppress the level of ATF4-CHOP and maintain a normal rate of global protein translation. To the extent that the pathway enables LPS-activated macrophages to carry out essential protein translation, it probably works in concert with complementary LPS-induced mechanisms that enhance translation initiation, such as mTOR-induced phosphorylation of 4E-BP1, which activates the initiation factor eIF4E (ref. 24) .
The mechanism of SFK deactivation by TLR-TRIF signalling will require further investigation, but our previous findings indicate that IRF5 and IRF7, but not IRF3, should have a role 3 . Interestingly, other studies have reported that LPS can activate SFKs, which, on the basis of the use of chemical inhibitors of SFKs in these reports, may be involved in certain LPS signalling pathways [25] [26] [27] . However, these studies are distinguished from the one here by their use of a much shorter LPS incubation time (30 min versus 14-24 h here). We found that the minimum LPS pre-incubation time that decreased the level of pTyr416-Src was 8 h, which is consistent with the time of LPS pre-treatment required for CHOP suppression 3 . This lag time may reflect the signalling events downstream of TLR-TRIF needed for LPS or poly(I:C) to induce the change in SFK activity. Moreover, previous studies in this area used an immortalized cell line derived from a leukaemia-virus-induced tumour (RAW 264.7) or retrovirus-immortalized bone marrow cells instead of primary macrophages. We found that ER-stressed tumour-cell-derived cell lines, including RAW 264.7 cells, are not responsive to the CHOP-suppressive effect of pathophysiologic relevant doses of LPS (C.W. Woo and I. Tabas, unpublished observations).
Future investigations will examine the relevance of this pathway to advanced atherosclerosis, where CHOP-induced macrophage apoptosis promotes plaque necrosis, a key feature of clinically dangerous plaques 28 . In advanced atherosclerotic lesions, the level of macrophage CHOP expression is very high despite the presence of numerous TLR ligands and evidence of macrophage TLR-TRIF activation 28, 29 . Therefore, we speculate that the CHOP-suppressive pathway becomes disabled in this setting, perhaps owing to interruption of one of the signalling components identified herein. Conversely, tumour cells, which often show evidence of UPR activation without UPR-induced apoptosis, can be become resistant to the protein-translation-inhibiting effects of p-eIF2α in the absence of LPS (ref. 30) . In one study with human breast cancer cells, this process was associated with an increase in the amount of eIF2B protein 31 , but it is possible that activation of eIF2Bε by dephosphorylation might play a role in 'p-eIF2α resistance' in other types of cancer cell. If so, strategies to disable eIF2B GEF-activating pathways that render cells resistant to p-eIF2α, such as the one described here, may decrease the resistance of certain types of cancer cell to ER-stress-induced cell death 32 . Thus, with further knowledge of the pathway described here, pharmacologic manipulation in one direction or the other may have unique therapeutic potential.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology Note: Supplementary Information is available on the Nature Cell Biology website METHODS Mice. C57BL6/J wild-type mice and Trif −/− mice (stock no. 005037) were purchased from the Jackson Laboratory.
Cell culture. Peritoneal macrophages were collected and cultured as previously described 3, 33 . MEFs were prepared and cultured as described previously 34 . siRNA, peptides, plasmids and adenoviral constructs. The C(α) subunit of PP2A and eIF2Bε were silenced using siRNA purchased from Qiagen (target sequence for PP2Ac, 5 -CAGGCTGCTATCATGGAATTA-3 ; for eIF2B, 5 -ACGGAAGTTG CAACTACAGTA-3 ). The coding sequences of wild-type and S535A-mutated rat eIF2Bε (ref. 35) were subcloned into the pcDNA3.1 expression plasmid as described previously 36 . Src activator peptide (Santa Cruz Biotechnology, sc-3052) was delivered to cells using a DirectX peptide transfection kit (Panomics). A plasmid encoding K296R-Y528F-mutated (dominant-negative) Src was purchased from Millipore. An adenoviral vector encoding kinase-inactive Src was a gift from B. Berk (University of Rochester, USA). The plasmids encoding wild-type and L199P-mutated (dominant-negative) PP2Ac were provided by B. Hemmings (Friedrich Miescher-Institut, Switzerland), and the plasmids encoding Y307Fmutated (constitutively active) PP2Ac were provided by D. L. Brautigan (University of Virginia, USA). The coding sequences of human wild-type eIF2Bε, S540A-S544A-mutated human eIF2Bε and S540D-S544D-mutated human eIF2Bε were prepared by Genewiz. In brief, eIF2Bε complementary DNAs (wild-type and mutant, GenBank: NM_003907) were amplified and a FLAG tag was inserted at the 5 end. The vector was then subcloned into pcDNA3.1(+). A CHOP-GFP reporter plasmid was provided by D. Ron (University of Cambridge, UK). This plasmid was constructed by fusing an 8.5-kilobase 5 murine CHOP gene fragment to enhanced GFP (ref. 37) .
Immunoprecipitation. Cells were lysed with a buffer containing 50 mM HEPES, 150 mM NaCl, 10 mM Na pyrophosphate, 10 mM EDTA, 10 mM EGTA, 1 mM Na orthovanadate, 50 mM NaF, 1 mM phenylmethyl sulphonyl fluoride, 5 µgml −1 leupeptin and 1% Triton-X. The cells or culture media were immunoprecipitated with anti-eIF2Bε (sc-55558) or anti-TNFα (sc-52746) antibody using an ImmunoCruz IP-WB Optima E System (Santa Cruz).
[ 35 S]methionine-cysteine incorporation into global proteins and TNFα.
Global protein synthesis was analysed as previously described 3 . For TNFα, the cells were labelled as described in the legend of Fig. 5 and Supplementary Fig. S4 . Medium and cells were immunoprecipitated using anti-TNFα, which recognizes both the pro-form (which has a relative molecular mass of 25,000, M r 25K) and the cleaved-secreted form (M r 17K). Approximately equal immunoprecipitated TNFα protein loads per lane were subjected to electrophoresis, and then transferred to a nitrocellulose membrane and immunoblotted for TNFα. For the medium experiment, the membrane was exposed to X-ray film for autoradiography, and the TNFα band was quantified by densitometry. For the cell experiment, the pro-TNFα bands on the immunoblot were cut out and their [ 35 S] c.p.m. was counted by liquid scintillation chromatography.
Immunoblot analysis. Immunoblots were conducted as described previously 38 .
All antibodies were purchased from Santa Cruz Biotechnology, except antip GSK-site -eIF2Bε, anti-p-eIF2α and anti-GFP (Abcam); anti-eIF2α and anti-pTyr416-Src (Cell Signaling Technology); and anti-Flag (Sigma-Aldrich). The dilutions of all primary antibodies were 1:500, except 1:1,000 for p-eIF2α and pTyr416-Src; and 1:3,000 for p-eIF2Bε.
Real-time quantitative PCR. Total RNA from cells was isolated and was reversetranscribed into cDNA as previously described 3 . Real-time quantitative PCR for Eif2be at the phospho-site region and amino-terminal region was conducted using Taqman PCR reagent (Applied Biosystems). For the Eif2be phospho-site region, the forward and reverse primers were 5 -GATGAG GAGCTACGGCAGAG-3 and 5 -CAGGACCTCGTTCTGGAAAA-3 , respectively; the FAM-labelled probe was 5 -TGGACAGCCGAGCAGGCT-3 . For the Eif2be N-terminal region, the forward and reverse primers were 5 -ATCTACCGAGGG CCTGAAGT-3 and 5 -TTTGACTCGCTCCTTGACCT-3 , respectively. Cyclophilin A was used as an internal control 3 . Real-time quantitative PCR for Tnfa was conducted using SYBR green reagent (Qiagen). The forward and reverse primers were 5 -CCAGACCCTCACACTCAG A-3 and 5 -CACTTG GTGGTTTGCTACGAC-3 , respectively.
TNFα ELISA. The level of TNFα in the culture medium was measured by an enzyme-linked immunosorbent assay kit (Thermo Scientific). eIF2Bε GEF activity assay. GEF activity was assayed as previously described 39 with a modification described in refs 40,41 . This assay uses a binary complex of eIF2-[ 3 H]GDP, which was formed by incubating 1.3 µM [ 3 H]GDP (10.7 Ci mmol −1 ) and rat liver eIF2 for 10 min at 30 • C in a mixture containing 50 mM MOPS, at pH 7.4, 100 mM KCl, 1 mM dithiothreitol, 200 µg ml −1 BSA and 2 mM Mg acetate. The reaction mixtures contained 175-µl of cell supernatant fraction in 140 µl of buffer D (50 mM MOPS, at pH 7.4, 209 µM GDP, 2 mM Mg acetate, 100 mM KCl, 1 mM dithiothreitol and 200 µg ml −1 BSA) and 87.5 µl of water. The reaction was initiated by adding 35 µl (1-2 pmol) of eIF2-[ 3 H]GDP binary complex (above) to the reaction mixture at 30 • C. After various reaction times, 75-µl aliquots were removed and placed in tubes containing 2.5 ml of ice-cold wash buffer (buffer D without BSA). The contents were mixed and immediately filtered through a nitrocellulose filter disc. The filters were dissolved in 7 ml of Filtron-X, and radioactivity was measured in a liquid scintillation counter. DOI: 10.1038/ncb2408 Macrophages were untreated or treated with hd-LPS (1 µg ml -1 ) for 24 h and then fixed with 4% paraformaldehyde and immunostained with antip-PP2Ac (red) and DAPI (blue). Bar, 20 µm. Quantification of percent of p-PP2Ac-positive macrophages is shown in the bar graph. *P < 0.03 vs. WT-con and both Trif -/groups. (b) Macrophages were incubated sequentially with hd-LPS for 6 h, followed by phosphate-free medium containing [ 32 P] orthophosphate and hd-LPS for 4 h and then hd-LPS in regular medium again for 14 h. Control cells went through an identical set of incubations but without LPS. Cell extracts were immunoprecipitated for eIF2Be, followed by SDS-PAGE and transfer to nitrocellulose. The membrane was exposed to X-ray film for autoradiography (top image) and then immunoblotted for eIF2Be (bottom image). Densitometric quantification of the autoradiogram ([ 32 P] p-eIF2Be):immunoblot (eIF2Be, 80 kDa) ratios is shown in the bar graph. *P < 0.04 vs. control. (c) Macrophages were untreated or pretreated with hd-LPS for 24 h and then fixed with 4% paraformaldehyde and immunostained with antip-Src (red) and DAPI (blue). Bar, 20 µm. Quantification of percent of p-Srcpositive cells is shown in the bar graph. *P < 0.03 vs. WT-con and both Trif -/groups. (d) Macrophages from wild-type and Trif -/mice were treated for 16 h in the absence (Con) or presence of hd-LPS, and the media were then assayed for TNFa by ELISA. *P < 0.05 vs. the control group. (e) Macrophages from wild-type and Trif -/mice were first treated for a total of 16 h in the absence (Con) or presence of hd-LPS, where the last 10 h included [ 35 S]methioninecysteine in the medium. The media were then immunoprecipitated using anti-TNFa or IgG control, and ~equal amounts of immunoprecipitated TNFa were loaded. After transfer to nitrocellulose, the membrane was exposed to X-ray film for autoradiography (top image) and then immunoblotted for TNFa (bottom image). Densitometric quantification of the autoradiogram:immunoblot TNFa band (17 kDa) ratios is shown in the bar graph. *P < 0.03 vs. WT control and both Trif -/groups. Data are expressed as mean ± s.e.m. with n = 3. 
